- Report
- October 2024
- 187 Pages
Global
From €3231EUR$3,545USD£2,759GBP
€3590EUR$3,939USD£3,066GBP
- Report
- April 2025
- 200 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- March 2025
- 200 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1823EUR$2,000USD£1,557GBP
- Report
- February 2024
- 135 Pages
Global
From €4329EUR$4,750USD£3,697GBP
- Report
- January 2024
- 89 Pages
Global
From €3500EUR$4,114USD£3,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2415EUR$2,650USD£2,063GBP
Rizatriptan is a medication used to treat migraine headaches. It belongs to a class of drugs known as triptans, which are used to treat moderate to severe migraine pain. Rizatriptan works by narrowing the blood vessels around the brain, reducing inflammation and relieving pain. It is available in both oral and nasal spray forms.
Rizatriptan is part of the Central Nervous System (CNS) drug market, which includes medications used to treat a variety of neurological conditions. These drugs are used to treat conditions such as depression, anxiety, epilepsy, and Parkinson's disease. The CNS drug market is highly competitive, with many different companies offering a variety of medications.
Some of the companies in the Rizatriptan market include Merck & Co., Inc., GlaxoSmithKline, Pfizer, Inc., and Teva Pharmaceuticals. Show Less Read more